TOP TIERMARKET NEWSWIRE

News & sentiment

NANOBIOTIX S A ADR (NBTX) — News & AI sentiment

NANOBIOTIX S A ADR (NBTX) news roundup. 6 stories in the past week, 11 over 30 days. Average 30-day sentiment is 60.5/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

6

avg sentiment 64.5/100

30d stories

11

avg sentiment 60.5/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

NBTX news in the last 24 hours, 7 days, 30 days and 90 days

How much NBTX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	NBTX stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	6	64.5/100	NBTX headlines →
Last 30 days	11	60.5/100	NBTX headlines →
Last 90 days	25	57.4/100	NBTX headlines →

Latest stories on NBTX

Why is Nanobiotix stock surging today?

Investing.com Markets64 · neutralgeneral

3d ago

Nanobiotix stock gains on positive melanoma trial data

Investing.com Markets74 · bullishproduct/pr

3d ago

Nanobiotix announces updated results from Phase 1 Study 1100 of JNJ-1900

The Fly58 · neutralproduct/pr

4d ago

Nanobiotix Melanoma Data Support Move to Randomized Trials for NBTXR3

TipRanks64 · neutralproduct/pr

5d ago

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

GlobeNewswire63 · neutralproduct/pr

5d ago

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

StockTitan64 · neutralproduct/pr

5d ago

Nanobiotix taps veteran biotech CFO Arnd Christ to steer next growth phase

TipRanks63 · neutralgeneral

Oct 1

Nanobiotix names new CFO

Seeking Alpha50 · neutralgeneral

Oct 1

Nanobiotix appoints Arnd Christ CFO

The Fly55 · neutralgeneral

Oct 1

NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer

GlobeNewswire56 · neutralgeneral

Oct 1

NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer

Business Insider55 · neutralgeneral

Oct 1

Nanobiotix advances cancer nanotherapeutics and bolsters cash runway into 2029

TipRanks63 · neutralproduct/pr

Sep 24

Nanobiotix GAAP EPS of -€0.70, revenue of €5.6M

Seeking Alpha34 · bearishearnings

Sep 24

NANOBIOTIX Provides First Half 2026 Operational and Financial Update

GlobeNewswire55 · neutralgeneral

Sep 24

NANOBIOTIX Provides First Half 2026 Operational and Financial Update

Business Insider55 · neutralgeneral

Sep 24

Guggenheim initiates Nanobiotix stock rating at Buy on cancer drug

Investing.com Analyst Ratings61 · neutralanalyst

Sep 15

Nanobiotix assumed with a Buy at Guggenheim

The Fly61 · neutralanalyst

Sep 15

At a glance: stocks gapping down premarket

Seeking Alpha34 · bearishgeneral

Sep 14

Nanobiotix announces updated safety, efficacy data from JNJ-1900 study

The Fly59 · neutralproduct/pr

Sep 14

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

Business Insider67 · bullishproduct/pr

Sep 14

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

GlobeNewswire67 · bullishproduct/pr

Sep 14

NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Business Insider56 · neutralgeneral

Sep 9

NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire56 · neutralgeneral

Sep 9

Nanobiotix Updates Share Capital and Voting Rights as of July 31, 2026

TipRanks50 · neutralgeneral

Aug 25

Nanobiotix Updates Share Capital and Voting Rights as of June 30, 2026

TipRanks50 · neutralgeneral

Jul 31

Open NBTX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →